Faculty

Institution

Unit

Venue

Lingegowda Selanere Mangala

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

The University of Texas MD Anderson Cancer Center

Lingegowda Selanere Mangala is a High Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on ovarian and endometrial cancer biology, particularly tumor immunogenicity, angiogenesis, and therapeutic resistance. His recent work has identified EGFL6 as a target for reprogramming tumor immunogenicity in ovarian cancer and explored epigenetic modulation of BARD1 and CD5L to overcome adaptive resistance to anti-VEGF therapy. He has also investigated EphA2- and HDAC-targeted combination therapies for endometrial cancer. His contributions span molecular biology, pharmacology, and oncogene research, with publications in Nature Communications, Cell Reports Medicine, and Cancer Research.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Lingegowda Selanere Mangala

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

cancer biology oncology tumor biology cancer research ovarian cancer pharmacology molecular biology gynecologic oncology cancer cells cell biology oncogenes tumor targeting medicinal research molecular cancer cancer treatment therapeutic targets cancer growth radiation oncology vascular biology gynecologic cancers cancer discovery cancer care cellular therapy carcinogenesis cancer genetics anti-cancer agents cancer genomics ovarian carcinoma tumor microenvironment tumor suppressors drug targeting pharmacotherapy molecular cell biology cell regulation angiogenesis enzyme inhibition rna biology oncogenic agent tumor growth cancer management novel therapies signaling pathways microrna detection non-coding rna clinical investigation long non-coding rna controlled release surgical oncology therapeutic efficacy viral oncology nano-drug delivery cancer risk fibroblast growth factors uterine cancer cell metabolism tumor heterogeneity neovascularization clinical medicine gene delivery adaptive resistance author correction endometrial cancer in vivo systems cell-matrix interactions colorectal cancer endocrine-related cancers src activation key switch liposomal sirna confers resistance chitosan nanoparticles mouse model tumor angiogenesis stromal glutamine synthetase tumors disrupts metabolic shifts

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 4303: Reprogramming Tumor Immunogenicity by Targeting Egfl6 in Ovarian Cancer. Cancer Research (2026)

tumor immunogenicitytumor biologycancer immunotherapycellular therapymolecular cancercancer biologycell biologyovarian cancercancer cellscarcinogenesisoncogenesimmunologytumor targetingtumor microenvironmentabstract 4303gynecologic oncology

Epigenetic Modulation of Bard1 to Enhance Anti-Vegf Therapy. Cell Reports Medicine (2025)

cell biologyoncogenesfibroblast growth factorsepigenetic modulationmolecular medicine

Expression of Concern for Jak2-Binding Long Noncoding Rna Promotes Breast Cancer Brain Metastasis. Journal of Clinical Investigation (2025)

metastasiscancer biologycell biologycancer cellsmolecular cell biologyoncogenesbrain tumor researchnon-coding rnamolecular biologycarcinogenesisbreast cancerlong non-coding rna

Abstract 3847: Dual Targeting of Egfl6 and Vegf-a to Overcome Immune Suppression in Ovarian Cancer. Cancer Research (2024)

Sujanitha UmamaheswaranLingegowda S. MangalaRobiya JosephNicholas B. JenningsMark S. KimYunfei WenEmine BayraktarNingyan ZhangZhiqiang AnAnil K. Sood

cancer researchcancer biologyovarian cancerimmunologyimmune suppression

Abstract 7549: Overcoming Resistance to Anti-Vegf Therapy via Epigenetic Regulation of Bard1. Cancer Research (2024)

epigeneticsmolecular cancernovel therapiescell biologycancer cellsabstract 7549oncogenesanti-vegf therapypharmacologyfibroblast growth factorstherapeutic targetsepigenetic regulationmolecular medicine

Epha2- and Hdac-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences (2024)

Robiya JosephSantosh K. DasariSujanitha UmamaheswaranLingegowda S. MangalaEmine BayraktarCristian Rodriguez-AguayoYutuan WuNghi NguyenReid T. PowellMary SobieskiYuan LiuMark Seungwook KimSara CorvignoKatherine FosterPahul HanjraThanh Chung VuMamur A. ChowdhuryPaola AmeroClifford StephanGabriel Lopez-BeresteinShannon N. WestinAnil K. Sood

gynecologycancer immunotherapyhdac-targeted combination therapygynecologic cancerstumor suppressorstherapeutic targetstumor biologyoncologycancer treatmentcancer discoverynovel therapiestumor targetinggynecologic oncologytumor heterogeneitybiomolecular engineeringmolecular sciencecancer cellsendometrial canceroncogenesmolecular biology

Abstract 1463: Fxr1 is an Oncogenic Driver in Ovarian Cancer. Cancer Research (2023)

Jasmine GeorgeIshaque P. KadamberiAnjali GeethadeviSudhir KumarSonam MittalCristian Rodriguez-AguayoLingegowda S. MangalaAnil K. SoodSunila PradeepPradeep Chaluvally-Raghavan

oncogenic driverovarian cancercancer research

Abstract 2720: Enhancing Oral Delivery of Plant-Derived Vesicles. Cancer Research (2023)

Yuan LiuAdrian Lankenau-AhumadaEmine BayraktarPaul SchwartzMamur ChowdhurySixiang ShiManu M. SebastianHtet KhantNatalia De ValZuliang JieNicholas B. JenningsCristian Rodriguez-AguayoJody SwainElaine SturLingegowda S. MangalaYutuan WuSupriya NagarajuBrooke ErimasChun LiGabriel Lopez-BeresteinJanet BraamAnil K. Sood

plant-derived vesiclesoncologycancer researchcancer biologycancer carebiotechnologyhealth sciencesoral deliverydrug delivery

Abstract 6001: Epigenetic Regulation of Bard1 Confers Resistance to Anti-Vegf Therapy in Ovarian Cancer. Cancer Research (2023)

Emine BayraktarCristian Rodriguez-AguayoSudhir KumarElaine SturLingegowda S. MangalaStephen BaylinGabriel Lopez-BeresteinSunila PradeepAnil K. Sood

epigeneticstherapy resistancecancer researchcancer biologyovarian canceranti-vegf therapymolecular biologyepigenetic changesepigenetic regulation

Combination of Epha2- and Wee1-Targeted Therapies in Endometrial Cancer. International Journal of Molecular Sciences (2023)

Santosh K. DasariRobiya JosephSujanitha UmamaheswaranLingegowda S. MangalaEmine BayraktarCristian Rodriguez-AguayoYutuan WuNghi NguyenReid T. PowellMary SobieskiYuan LiuMamur A. ChowdhuryPaola AmeroClifford StephanGabriel Lopez-BeresteinShannon N. WestinAnil K. Sood

gynecologyoncologycancer researchmedicinal researchendometrial cancerpharmacologycancer treatmenttherapeutic targetstumor targetingmolecular biologygynecologic oncology

1
2
3
4
5
17
10 / page

Lingegowda Selanere Mangala

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Lingegowda Selanere Mangala

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 4303: Reprogramming Tumor Immunogenicity by Targeting Egfl6 in Ovarian Cancer. Cancer Research (2026)

Epigenetic Modulation of Bard1 to Enhance Anti-Vegf Therapy. Cell Reports Medicine (2025)

cell biologyoncogenesfibroblast growth factorsepigenetic modulationmolecular medicine

Expression of Concern for Jak2-Binding Long Noncoding Rna Promotes Breast Cancer Brain Metastasis. Journal of Clinical Investigation (2025)

metastasiscancer biologycell biologycancer cellsmolecular cell biologyoncogenesbrain tumor researchnon-coding rnamolecular biologycarcinogenesisbreast cancerlong non-coding rna

Abstract 3847: Dual Targeting of Egfl6 and Vegf-a to Overcome Immune Suppression in Ovarian Cancer. Cancer Research (2024)

Sujanitha UmamaheswaranLingegowda S. MangalaRobiya JosephNicholas B. JenningsMark S. KimYunfei WenEmine BayraktarNingyan ZhangZhiqiang AnAnil K. Sood

cancer researchcancer biologyovarian cancerimmunologyimmune suppression

Abstract 7549: Overcoming Resistance to Anti-Vegf Therapy via Epigenetic Regulation of Bard1. Cancer Research (2024)

Epha2- and Hdac-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences (2024)

Abstract 1463: Fxr1 is an Oncogenic Driver in Ovarian Cancer. Cancer Research (2023)

Jasmine GeorgeIshaque P. KadamberiAnjali GeethadeviSudhir KumarSonam MittalCristian Rodriguez-AguayoLingegowda S. MangalaAnil K. SoodSunila PradeepPradeep Chaluvally-Raghavan

oncogenic driverovarian cancercancer research

Abstract 2720: Enhancing Oral Delivery of Plant-Derived Vesicles. Cancer Research (2023)

plant-derived vesiclesoncologycancer researchcancer biologycancer carebiotechnologyhealth sciencesoral deliverydrug delivery

Abstract 6001: Epigenetic Regulation of Bard1 Confers Resistance to Anti-Vegf Therapy in Ovarian Cancer. Cancer Research (2023)

Emine BayraktarCristian Rodriguez-AguayoSudhir KumarElaine SturLingegowda S. MangalaStephen BaylinGabriel Lopez-BeresteinSunila PradeepAnil K. Sood

epigeneticstherapy resistancecancer researchcancer biologyovarian canceranti-vegf therapymolecular biologyepigenetic changesepigenetic regulation

Combination of Epha2- and Wee1-Targeted Therapies in Endometrial Cancer. International Journal of Molecular Sciences (2023)

gynecologyoncologycancer researchmedicinal researchendometrial cancerpharmacologycancer treatmenttherapeutic targetstumor targetingmolecular biologygynecologic oncology

1
2
3
4
5
17
10 / page